Syracuse

Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Archive ouverte

Espinosa, Eric | Valitutti, Salvatore | Laroche, Michel | Laurent, Camille | Apoil, Pol-André | Hermine, Olivier | Lavit, Michel | Paul, Carle | Bulai Livideanu, Cristina

Edité par CCSD ; Elsevier -

International audience. There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (n = 2) and mast cell activation syndrome (n = 2). We show that this molecule reduces the long-term survival of primary human mast cells, interferes with lysosome function and leads to the accumulation of non-functional tryptase in the mast cell granules. Furthermore, hydroxychloroquine decreases the production of pro-inflammatory mediators.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion